FBIO Stock Forecast: Fortress Biotech, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.90
+7.34% on the day

The median 12-month analyst price target for Fortress Biotech, Inc. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 87 of 100 as at 21 Nov 2026 — inside the top quartile.

Market cap
$64.1M
Ticker Nerd rank
87/ 100
Median analyst target
$5.00
Analysts covering
1
Revenue$18.7M+14.0% y/y
Operating income−$10.0M
Net income$602K
Free cash flow−$59.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.1%
1M
−2.1%
YTD
−48.1%
1Y
−24.9%
From 52W high
−56.6%
From 52W low
+11.1%
$1.71
$4.38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Fortress Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
87/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
94
Quality
93
Volatility
77
Issuance
62
Revisions
59
Accruals
53
Value
52
Momentum
40

Growth (94): Sales and profits are climbing, and climbing faster than before.

Momentum (40): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

FBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26FBIOHigh $5.00Median $5.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$5.00
Low
$5.00
Median
$5.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
23 Feb 2026HC Wainwright & Co.ReiteratesBuy$17
21 Aug 2025HC Wainwright & Co.MaintainsBuy—
11 Mar 2025Roth MKMReiteratesBuy—
18 Nov 2024HC Wainwright & Co.MaintainsBuy—
19 July 2024HC Wainwright & Co.ReiteratesBuy—
20 June 2024Cantor FitzgeraldReiteratesOverweight—
16 May 2024Roth MKMReiteratesBuy—
19 Mar 2024Alliance Global PartnersInitiatesBuy—
15 Mar 2024Roth MKMReinstatesBuy$10
29 Nov 2023Roth MKMMaintainsBuy—
15 Aug 2023Cantor FitzgeraldReiteratesOverweight$5.00
16 May 2023Cantor FitzgeraldMaintainsOverweight$6.00 → $5.00
6 Apr 2023BenchmarkReiteratesSpeculative Buy$5.00
4 Aug 2022Ladenburg ThalmannInitiatesBuy$6.00
14 July 2022B. Riley SecuritiesMaintainsBuy$8.00 → $6.00
20 Apr 2021Roth CapitalMaintainsBuy$4.50 → $5.00
13 Oct 2020Roth CapitalMaintainsBuy$5.00 → $4.75
12 Oct 2020HC Wainwright & Co.MaintainsBuy$11 → $10
2 Oct 2020BenchmarkInitiatesBuy—
13 Mar 2020B. Riley FBRMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FBIO.

Market Radar

This page is one stock. Monday covers all of them.

FBIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

FBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Fortress Biotech, Inc. returned −24.9% against +6.9% for the S&P 500, dividends included.

FBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Jan 26Apr 26Jul 26Oct 26FBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+6.3%
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.8×

Cheaper than 93% of US stocks

Price / sales
0.9×

Cheaper than 68% of US stocks

Price / book
0.4×

Cheaper than 89% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
67.2%

Higher than 80% of US stocks

Operating margin
−42.8%

Higher than 19% of US stocks

Net margin
—
Returns & dividend
Return on equity
102.5%

Higher than 96% of US stocks

Return on assets
−8.1%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Fortress Biotech, Inc. has a market value of $64.1M.

  • Revenue in the twelve months to 30 June 2026: $68.5M. The latest quarter grew 14.0% year on year.

  • Net income over the same four quarters: $141.2M, a 206.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $125.8M.

  • Fortress Biotech, Inc. spent $14.3M on share buybacks and $473K on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 33.3M.

  • Trailing P/E: 0.8×.

  • Fortress Biotech, Inc. employs 78 people — $878K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

FBIO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FBIOFortress Biotech, Inc.$64.1M87
ATRAAtara Biotherapeutics, Inc.$63.5M74
MNOVMediciNova, Inc.$64.4M88
VTVTvTv Therapeutics, Inc.$61.1M69
TNYATenaya Therapeutics, Inc.$65.3M50
GOSSGossamer Bio, Inc.$65.5M65
NMRANeumora Therapeutics, Inc.$60.8M35

Take a look at FBIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Fortress Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about FBIO

What is the FBIO stock price forecast for 2026-2027?

The median 12-month analyst price target for Fortress Biotech, Inc. is $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FBIO stock a buy right now?

Of the 1 analyst covering Fortress Biotech, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fortress Biotech, Inc. 87 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FBIO?

As at 21 Nov 2026, Fortress Biotech, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).

Will FBIO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $5, and Ticker Nerd's factor model ranks Fortress Biotech, Inc. 87 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FBIO stock forecast for 2030?

No analyst covering Fortress Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.

How has FBIO stock performed over the past year?

Fortress Biotech, Inc. returned -24.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fortress Biotech, Inc. do?

Fortress Biotech, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing pharmaceutical and biotechnology products. Fortress Biotech operates through two core areas: dermatology product sales and pharmaceutical and biotechnology product development.

Company

About Fortress Biotech, Inc.

Fortress Biotech, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing pharmaceutical and biotechnology products. Fortress Biotech operates through two core areas: dermatology product sales and pharmaceutical and biotechnology product development. Its commercial portfolio includes prescription and specialty dermatology therapies used for conditions such as acne, rosacea, hyperhidrosis, and other skin-related disorders, alongside wound-care and supportive treatment products. The company also advances a broader pipeline and portfolio of assets through its subsidiary and partner network, supporting programs in areas such as rare diseases and oncology. Fortress Biotech plays a role in the healthcare market by combining product sales with asset development, royalties, and other collaboration-based revenue streams. Headquartered in Bay Harbor Islands, Florida, Fortress Biotech serves a range of medical professionals and patients across the United States and international markets.

CEO Dr. Lindsay Allan Rosenwald M.D. · 78 employees · United States · https://www.fortressbiotech.com